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Adoptive Cell Transfer (ACT) of Tumor-Inﬁltrating Lymphocytes (TIL) in combination with lymphodepletion has proven to be
an eﬀective treatment for metastatic melanoma patients, with an objective response rate in 50%–70% of the patients. It is based
on the ex vivo expansion and activation of tumor-speciﬁc T lymphocytes extracted from the tumor and their administration back
to the patient. Various TIL-ACT trials, which diﬀer in their TIL generation procedures and patient preconditioning, have been
reported. In the latest clinical studies, genetically engineered peripheral T cells were utilized instead of TIL. Further improvement
of adoptive T cell transfer depends on new investigations which seek higher TIL quality, increased durable response rates, and aim
to treat more patients. Simplifying this therapy may encourage cancer centers worldwide to adopt this promisingtechnology. This
paper focuses on the latest progress regarding adoptive T cell transfer, comparing the currently available protocols and discussing
their advantages, disadvantages, and implication in the future.
1.Introduction
Metastatic melanoma is a highly aggressive cancer. It is the
s i x t hm o s tc o m m o nc a n c e rt y p ei nm e na n dt h es e v e n t hi n
woman and has a poor prognosis with a median survival of
6–10 months and a 5 year survival rate of about 10% [1, 2].
So far, only two drugs have been approved by the Food and
Drug Administration (FDA) for the treatment of metastatic
melanoma patients,the chemotherapeuticagentdacarbazine
(DTIC) and the immunomodulator Interleukin-2 (IL-2).
DTIC is an antineoplastic chemotherapy drug used in the
treatment of various cancers [3, 4], which alkylates and
crosslinks DNA during all phases of the cell cycle, result-
ing in disruption of DNA function, cell-cycle arrest, and
apoptosis [5] .D T I Ca sas i n g l ea g e n tc a ni n d u c eo b j e c t i v e
tumor regression in 15%–20% of metastatic melanoma
patients with median response duration of 5 to 6 months
and a negligible complete response rate [6]. The admin-
istration of IL-2 activates endogenous antitumor reactive
T cells and NK cells resulting in a 20%–30% objective
response rate, with complete regression in only 5%–8% of
the melanoma patients [7–9]. Chemobiotherapy, combining
low-dose IL-2 and chemotherapy, demonstrates a similar
response rate to that of high-dose IL-2 alone, with 7%
of the patients achieving a durable complete response [10,
11].
In the past decade, various therapeutic approaches for
metastatic melanoma patients have been tested, most of
them with unsatisfactory clinical results. The discovery of
melanoma-speciﬁc tumor associated antigens paved the way
for the use of immunotherapy [12]. Immunotherapy is an
innovative approach which includes: (1) cytokines, such
as IL-2 and IFNα, which stimulate immune eﬀector cells,
(2) monoclonal antibodies, against cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4) or programmed death 1
(PD-1), (3) intratumoral gene transfer with genes encoding
for example forgranulocyte-macrophage colony-stimulating
factor (GM-CSF), (4) active immunization via vaccination
with peptides, dendritic cells, recombinant viruses encod-
ing tumor-associated antigens (TAA), and costimulatory
molecules or whole tumor cell vaccines, and (5) adoptive T
cell transfer.2 Clinical and Developmental Immunology
Like IL-2, IFNα is FDA approved, but only for adjuvant
treatment ofstageIIImelanoma patientsandnotforpatients
with metastatic disease [11]. The monoclonal antibody
ipilimumab, which blocks the inhibitory eﬀects of CTLA-
4 on T cells, was evaluated in a randomized phase III
study and showed an improved overall survival compared
to glycoprotein 100- (gp100-) derived peptide vaccines.
However, adverse events were sometimes severe or long
lasting [13].
In the past few years, the ﬁeld of intratumoral gene
transfer has been established. A very encouraging phase
II study conducted on 43 melanoma patients reported an
almost 30% objective response with very minor side eﬀects
following intratumoral injection of a viral vector encoding
for GM-CSF [14]. On the other hand, various cancer
vaccines trials have failed so far, as they demonstrated a very
low objective response rate of only 3%-4% [15].
Among the current immunotherapy approaches, ACT
therapy using autologous tumor inﬁltrating lymphocytes
(TIL)hasshowntobeaneﬀectivetreatmentforpatientswith
metastatic melanoma and can mediate objective response
rates between 50%–70% with manageable toxicity [16–
18]. Furthermore, the ability to genetically engineer tumor
antigen speciﬁc lymphocytes may enable the use of ACT
to a wider patient population and for treatment of other
malignancies. This paper summarizes and compares the
diﬀerent ACT approaches and discusses their advantages,
disadvantages, and challenges.
2.InitialACT Studies
Adoptive cell transfer immunotherapy relies on the transfer
of ex vivo expanded and activated tumor-speciﬁc lympho-
cytes to the autologous tumor-bearing host. In the 1980s,
the availability of recombinant IL-2 for in vitro use brought
the breakthrough of ACT trials [19–21]. Using IL-2 as a T
cell growth factor in culture promoted the ability to expand
human lymphocytes to larger scales and for longer periods.
The ﬁrst generation of ACT utilized lymphokine-activated
killer (LAK) cells with high-dose IL-2 for the treatment of
patients with advanced cancer but was not shown to be
superior to the treatment of IL-2 alone [22]. In vitro lysis or
cytokine release assays revealed that expanded LAK cells did
not exhibit any anti-tumor activity [23].
The second generation of ACT employed tumor-
inﬁltrating lymphocytes instead of LAK cells. TIL are T
cells present within the tumor of the patient, which have
the ability to speciﬁcally recognize tumor antigens and
thereby eliminate malignant cells. However, in most cancer
patients, those naturally occurring TIL fail to destroy the
tumor as they are outnumbered, not fully activated, or
suppressed. Therefore, the main objective of TIL-ACT is the
production of large numbers of activated tumor-speciﬁc T
cells. Furthermore, patients receive IL-2 immediately after
TIL infusion to further activate the administered TIL. In
most current protocols, high-dose intravenous bolus IL-2
(720,0001IU/kg)isadministeredintravenouslyevery8hours
to tolerance or to a maximum of 15 doses.
An initial TIL-ACT trial for metastatic melanoma
patients was published in 1988 and summarized in 1994
by Rosenberg et al. at the National Cancer Institute (NCI),
Bethesda [24, 25]( Table 1,r o wA ) .I nt h i ss t u d y ,8 6c o n -
secutive patients were treated with autologous TIL including
high-dose intravenous bolus IL-2. TIL single-cell suspension
was generated bythe enzymatic digestion ofthe entire tumor
and expanded in a high concentration of IL-2. After 2-3
weeks, the cultures were cleared of tumor cells and lympho-
cytes were further expanded until they reached a number
of 109 cells. Then, the cells were transferred from tissue
culture plates to cell culture bags and cultured until at least
1011 TIL were generated. TIL and IL-2 were administered in
two cycles separated by approximately 2 weeks. Fifty-seven
of the 86 patients received an additional single low dose
of cyclophosphamide (25mg/kg) approximately 36 hours
before receiving the ﬁrst TIL infusion. The overall objective
response rate was 34% and comparable to studies with
high-dose IL-2 alone (31%) or IL-2-based chemobiotherapy
(35%). Only 5 of the patients experienced a complete
response, and the median survival of all partial responders
was just 4 months. Analysis of the survival of the transferred
cells in vivo using cells genetically labeled with neomycin
phosphotransferase demonstrated a lackofpersistence ofthe
infused cells.ThepersistenceoftheTILinthecirculationwas
barely 0.1% one week after administration [26]. Neverthe-
less, this initialstudy demonstratedthatTIL-ACT canindeed
cause clinical remission although response rates were low at
that time.
A retrospective analysis comparing TIL characteristics
of responding versus nonresponding patients revealed that
responders were treated with TIL that spent less time in
culture, had shorter doubling times, and exhibited higher
in vitro lysis against autologous tumor targets [27, 28].
Additionally, patients who received TIL generated from
subcutaneoustumorlesionshadhigherresponse rates(49%)
compared to those receiving TIL from lymph nodes (17%),
probably as lymph nodes contain many unspeciﬁc T cells
[27].
The results of this study indicated the importance of
as u i t a b l ein vitro selection process which can detect anti-
tumor speciﬁc TIL.
This pioneer trial paved the way for new clinical studies
designed to improve the TIL anti-tumor speciﬁcity, the
growth and expansion conditions, and the creation of
younger TIL culture with higher persistence and lower
senescence.
3.CurrentTIL Studies
3.1. The “Selected-TIL” Protocol. Earlier studies utilized bulk
TIL cultures that contained heterogeneous populations of
lymphocytes,onlysomeofwhichshowedanti-tumoractivity
in vitro [24, 25]. Studies of the T-cell receptor rearrange-
ments in TIL revealed the variability of T cells present in
these cultures and emphasized the need to develop culture
techniques that speciﬁcally select anti-tumor reactive cell
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not contribute to the therapeutic eﬀect [29]. It is known
that T cells recognize tumor antigens in an MHC-restricted
manner when the appropriate human leukocyte antigen
(HLA) restriction element is present [30–32]. Upon antigen
recognition cytotoxicT cells secrete the cytokineIFNγ which
canbe measured bya simple enzyme-linked immunosorbent
assay (ELISA). The integration of an IFNγ release-based in
vitro assay, which allows the selection of antigen-speciﬁc TIL
is the core element of the Selected-TIL protocol (Table 1,
row B) [33–35].
The generation of Selected-TIL with speciﬁc reactivity
against tumor antigens consists of three stages.
(1) Isolation and generation of TIL from the tumor.
Several methods can be used for initiating TIL and
melanoma cultures from the resected tumor. TIL cultures
are usually established by cutting the resected tumor spec-
imens into 1–3mm3 fragments from diﬀerent areas of the
tumor. Approximately 8–10 single fragments are placed into
diﬀerentwellsofatissue cultureplate,and eachobtainedTIL
culture is maintained independently. This method generates
multiple TIL cultures and enables the in vitro screening of
every individual culture. Besser et al. showed that for 97% of
thepatientsatleastoneTIL culturecanbegeneratedwhereas
a primary melanoma cell culture can be established from
70% of the resected tumor [36]. Generating TIL cultures
from a single small fragment and expanding those cells to
approximately 50 × 106 cells, a suitable number to initiate
large scale expansion, requires 21–36 days.
(2) In vitro TIL selection.
Each individualTILcultureisscreenedfortumorspeciﬁc
reactivity by coincubationofTIL with autologousmelanoma
cells over night, followed by the measuring of IFNγ levels.
Alternatively, a HLA-A2 matched melanoma cell line can
be used for TIL cultures from HLA-A2 positive patients.
TIL pass the screening process, if IFNγ secretion exceeds
200pg/ml and double the level of a control in which the TIL
are coincubated with any HLA-mismatched melanoma cell
line [37, 38]. Only individual TIL cultures complying with
this criterion can be used for further large-scale expansion.
(3) Large-scale expansion.
Afterreaching 50 ×106 cells,TILaremassivelyexpanded,
resulting in an approximately 1000-fold expansion and a
ﬁnal cell number of about 50 × 109 TIL. This rapid expan-
sion process (REP) requires anti-CD3 antibody, irradiated
peripheral blood mononuclear feeder cells and IL-2. The
large-scale expansion process is a standardized procedure
w h i c hr e q u i r e s1 4d a y s[ 36, 37] and results in the production
of high numbers of activated TIL ready for administration.
Response rates are assessed using the Response Evalu-
ation Criteria In Solid Tumors (RECIST) guidelines [39]
and Objective Responses (OR) includeComplete Remissions
(CR) and Partial Responses (PR).
A major breakthrough in the ﬁeld of ACT was the addi-
tion of lymphodepleting NonMyeloablative Chemotherapy
(NMC). NMC is given in order to suppress endogenous
regulatory T cells and to provide the optimal environment
for the infused TIL. Various mouse models have shown
the marked eﬀect of lymphodepletion on the eﬃcacy of
T cell transfer trials (reviewed in [40]). In 2002, Dudley
et al. conducted a Selected-TIL study in which all TIL
patients received NMC starting 7 days prior TIL infusion
(day 0). On days −7a n d−6, patients were treated with
cyclophosphamide (60mg/kg) and on days −5t o−1w i t h
ﬂudarabine (25mg/m2). Six of 13 (47%) patients achieved
an objective response with signiﬁcant shrinkage of the
tumors (Table 1,r o wB )[ 41]. The addition of NMC before
TIL administration resulted in the persistent repopulation
of anti-tumor T cells in the patients, with proliferation
of functionally active transferred cells in vivo and the
traﬃcking to tumor sites. A further study was conducted
by Dudley et al. three years later including 35 patients,
reported 18 (51%) patients that experienced OR including
three ongoing complete remissions and 15 (42%) partial
responses with a mean progression-free survival of 11.5
months [17]. The toxicities associated with this treatment
included the expected toxicities of high-dose IL-2 therapy,
such as hypotension, pulmonary congestion, vascular leak
syndrome, and bone marrow suppression associated with
lymphodepleting chemotherapy. Some patients exhibited
autoimmune manifestations, such as vitiligo and uveitis,
caused by destruction of melanocytes in skin and eyes.
Toxicities were mostly transient and readily managed by
standard supportive techniques with no treatment-related
deaths.
The Selected-TIL protocol including lymphodepleting
preconditioning of the patient was indeed a major improve-
ment to earlier TIL protocols. Though, the main disadvan-
tage of this approach was the extremely high dropout rate
of enrolled patients. In a report conducted in 2009, it was
shown that abouttwo thirds ofall enrolled patients had to be
excluded from the treatment [36]. This high dropout rate is
the result of two major reasons, directly related to the in vitro
IFNγ screening process: (1)failure to establish an autologous
melanoma line for HLA-A2 negative patients which is
essential to perform the screening (approximately 30%) and
(2) absence of TIL cultures secreting IFNγ (approximately
40%) [16, 36]. A few more patients were excluded due
to clinical deterioration or as TIL cultures could not be
established [36].
Due to the high dropout rate, a diﬀerent criterion which
relates to clinical response was required. Interestingly, in
1994, Schwartzentruber et al. could not correlate IFNγ
secretion to clinical outcome [27]. On the other hand,
characteristics that were repeatedly reported to have a
signiﬁcant positiveassociationtoclinicalresponse wereshort
TIL culturedurationandtelomere length[27, 28, 42–44]. An
invitro studycomparingyoungerTILculturestoolderIFNγ-
Selected-TIL showed that TIL spending less time in culture
have longer telomeres and high levels of the costimulatory
molecules CD27 and CD28, which can lead to persistence in
vivoaswellasobjectiveresponses[42–46].Theseinvitro data
led to the development of the so called Young-TIL protocol
[16, 36].
3.2. The “Young-TIL” Protocol. The Young-TIL protocol
utilizes bulk unselected TIL, which spend minimal time in
culture (Table 1, row C). In contrast to the Selected-TIL4 Clinical and Developmental Immunology
Table 1: Comparison of published adoptive T cell transfer studies for melanoma patients.
Tc e l lt y p e Origin of T
cell Culture initiation In vitro screening Large-scale
expansion protocol
Patient
conditioning OR (%) Ref
AT I L Melanoma
biopsy
O n es i n g l eb u l k
culture None
Cells grown with
IL-2 till desired
number obtained
Cyclophosphamide 35 [24, 25]
B Selected-TIL Melanoma
biopsy Multiple cultures IFNγ ELISA anti-CD3, IL-2,
IFC for 14 days NMC 50 [17, 41]
CY o u n g - T I L Melanoma
biopsy
O n es i n g l eb u l k
culture None anti-CD3, IL-2,
IFC for 14 days NMC 50 [16]
D Selected-TIL Melanoma
biopsy Multiple cultures IFNγ ELISA anti-CD3, IL-2,
IFC for 14 days NMC + 2 Gy TBI 52 [18]
E Selected-TIL Melanoma
biopsy Multiple cultures IFNγ ELISA anti-CD3, IL-2,
IFC for 14 days NMC + 12 Gy TBI 72 [18]
F Engineere T
cells Leukopheresis
Gene therapy with
low-aﬃnity
MART-1 TCR
IFNγ ELISA,
Transductio eﬃciency various protocols NMC 12 [56]
G Engineere T
cells Leukopheresis
Gene therapy with
high-aﬃnity
MART-1 TCR
IFNγ ELISA,
Transductio eﬃciency various protocols NMC 30 [60]
H Engineere T
cells Leukopheresis Gene therapy with
gp100 TCR
IFNγ ELISA,
Transductio eﬃciency various protocols NMC 19 [60]
(TIL) Tumor inﬁltrating lymphocytes, (OR) objective response, (Ref) Reference, (IFC) irradiated feeder cells, (NMC) nonmyeloablative chemotherapy, and
(TBI) total body irradiation.
protocol, Young-TIL are initiated from a single cell sus-
pension obtained after enzymatic digestion of the resected
tumorandnotfrommultiplesmallfragments.Consequently,
the number of TIL is higher in the initial culture which
enables the generation of a TIL culture ready for expansion
in only 10 to 18 days [45]. Young-TIL are considered
ready for expansion when they reach a number of at least
50 × 106 cells and all melanoma cells are eliminated.
The process of growing a single TIL culture enormously
simpliﬁes the laboratory procedure and lowers costs. In
a study from 2010, Besser et al. showed that Young-TIL
cultures were successfully established for nearly 90% of the
patients(Table 1,r o wC ) .A sn of u rth e rs e l e cti o np r o c e s sw a s
required, all established Young-TIL cultures were eligible for
treatment. This resulted in a dramatic improvement of the
proportion of treated patients compared to the Selected-TIL
protocol with a drop-out rate of only 26%, mainly caused
by clinical deterioration of patients during TIL preparation
[16].
TIL large-scale expansion, preconditioning of the
patients with NMC and administration of high-dose IL-2
following cell transfer were identical to Selected-TIL ACT.
IL-2 and chemotherapy-related toxicities as well as response
rate were comparable to the Selected-TIL protocol. Ten of 20
(50%) metastatic melanoma patients experienced a clinical
objective response including two ongoing CR and eight
PR [16]. The signiﬁcant correlation between short culture
durationand clinicalresponse wasconﬁrmed.Allresponders
received TIL cultures which were established within 19
days, which then continued to the large-scale expansion
process.
In conclusion, Young-TIL ACT as compared to Selected-
TIL ACT has the major advantage of being less labor inten-
sive, requires less laboratory expertise, enables the treatment
of most enrolled patients, and still results in an objective
response rate of 50%.
This process simpliﬁcation might be essential as it may
integrate ACT to more cancer centers worldwide and thus
expose new patients to this eﬀective therapy.
3.3. “Selected-TIL” ACT with Addition of Total Body Irradi-
ation. Studies on murine ACT models have demonstrated
the need for lymphodepletion prior to TIL transfer in order
to eliminate suppressive CD4+CD25+ T-regulatory cells as
well as normal endogenous lymphocytes that compete with
the transferred cells for homeostatic cytokines such as IL-7
and IL-15. These studies reported a signiﬁcant correlation
between the intensity of lymphodepletion and the in vivo
antitumor eﬀect of the infused cells [40, 47–50]. Non-
myeloablative chemotherapy using cyclophosphamide and
ﬂudarabine are given to deplete the lymphoid compartment
of patient and to provide the optimal environment for the
infused anti-tumor lymphocytes. Addition of total body
irradiation (TBI) can further augment lymphodepletion.
In order to validate if enhanced lymphdepletion can
further increase response rate, a series of three nonran-
domized clinical trials were conducted with a total of 93
metastatic melanoma patients between the years 2002 and
2008 [17, 18, 41]. In all three studies, TIL were established
according to the Selected-TIL protocol. Until 2008 a total
of 43 patients were treated with the Selected-TIL protocol
in combination with NMC at the NCI, Bethesda, of whichClinical and Developmental Immunology 5
Table 2: Adoptive T cell transfer trials currently recruiting patients.
NCT ID Sponsors Phase Study design Pat. No. Transferred cells TBI NMC IL-2
00287131 Sheba Medical Center II NR 20 Selected or Young-TIL − ++
00338377
M.D. Anderson
Cancer Center Chiron
Corporation
II R 83
TIL versus TIL with
dendritic cell
immunization
− ++
01118091 National Cancer
Institute II R 135 IL-2 versus IL-2 with
enriched Young TIL CD8
− ++
00513604 National Cancer
Institute II NR 149 TIL +/− CD4+ depletion − ++
00910650
University of
California;California
Institute of Technol.
Univer. of Southern
CaliforniaUniversity
of Connecticut
II NR 22
anti-MART-1TCR-gene
engineered lymphocytes
and MART-1 peptide
pulsed dendritic cells
− ++
00612222 National Cancer
Institute II NR 41
anti-MART-1 TCR-gene
engineered lymphocytes
and ALVAC virus
immunization
− ++
00610311 National Cancer
Institute II NR 41
anti-gp100 TCR-gene
engineered lymphocytes
and ALVAC virus
immunization
− ++
00512889 Dana-Farber Cancer
Institute IN R2 0
MART1/Melan-A speciﬁc
CTL +/− GM-CSF and
irradiation of cutaneous
tumor lesion
−−−
01082887 Nantes University
Hospital I/II NR 12
TIL in combinationwith
intra-tumoral injections
of IFNγ adenovirus
(Ad-IFNγ)
−−+( s . c )
00324623 Centre Hospitalier
Universitaire Vaudois IN R1 2
Melan-A/MART-1
antigen-speciﬁcCD8 T
lymphocytes
− + −
00814684 National Cancer
Institute II R 95
anti-Mart-1 and peptide
vaccines versus
anti-gp100 TCR-gene
engineered lymphocytes
and peptide vaccines
++−
00670748 National Cancer
Institute II NR 82
anti-NY ESO-1
TCR-Gene engineered
lymphocytes
− + −
01029873
Altor Bioscience
Corporation;
National Cancer
Institute
I/II NR 58
Cisplatin with ALT-801
(IL-2 fused to T-cell
receptor directed against
p53-derived peptides)
−−−
00393029 National Cancer
Institute II NR 12 anti-p53 TCR-gene
engineered lymphocytes
− ++
00871481
Fred Hutchinson
Cancer Research
Center; National
Cancer Institute
I/II ∗∗∗ 30
Autologous NY-ESO-1-
melanoma-speciﬁc CD8+
T cells +/− ipilimumab
− ++ ( s . c )
01106235
Fred Hutchinson
Cancer Research
Center
IN R1 0
Autologous IL-21
modulated CD8+
antigen-speciﬁc T cells
− ++ ( s . c )
00925314 Cosmo Bioscience II NR 20
CB-10-01 (transgenic
lymphocyte
immunizationagainst
telomerase)
−−−6 Clinical and Developmental Immunology
Table 2: Continued.
NCT ID Sponsors Phase Study design Pat. No. Transferred cells TBI NMC IL-2
00062036 National Cancer
Institute I/II NR 33 IL-2 gene-transduced TIL − ++
00924001 National Cancer
Institute I/II NR 30
Allogeneic tumor-reactive
lymphocyte cell line
DMF5
− ++
All clinical trials are registered on http://www.clinicaltrials.gov/; (NCT ID) Clinical trial identiﬁer, (Pat. No.) Number of treated patients, (R) Randomized,
(NR) none randomized, (∗∗∗) not reported, (TIL) tumor inﬁltrating lymphocytes, (TBI) total body irradiation, (NMC) nonmyeloablative chemotherapy,
(s.c)subcutaneous.
the result of the ﬁrst 35 patients were discussed earlier [17]
(see Section 3.1, Table 1, rowB).Inasecondtrial, 25patients
received 2-Gy TBI in addition to NMC one day before
cell administration (Table 1, row D). In the third study, 25
patientsreceived a total of 12-Gy TBI, 2-Gy was giventwice a
day for three consecutive days in addition to NMC (Table 1,
row E) [18]. All TBI patients received autologous puriﬁed
CD34+ hematopoietic stem cells one or two days after TIL
infusion.
Objective responses were demonstrated in 49% (21 of
43) of patients receiving NMC alone, 52% (13 of 25) of the
patients treated with NMC and 2-Gy TBI, and 72% (18 of
25) among patients with NMC and 12-Gy TBI [18]. The
highest rate of complete remissions was achieved in the 12-
GyTBIgroupwith 28%,ascomparedto8%and6%inthe2-
Gy TBI and the no TBI-treated patients, respectively. The 2-
year survival rates were 42% and 30% in the trials with 2-Gy
TBI and no TBI, respectively, while followup was too short
in the 12-Gy TBI group. Patients treated with 12-Gy TBI
demonstrated a 1-2daysdelayinmarrow recoverycompared
to all other protocol patients and required signiﬁcantly more
blood product support than patients treated with 2-Gy TBI.
Furthermore, several toxicities such as fatigue, anorexia,
and weight loss were more prolonged in patients treated
with 12-Gy TBI, with returning to normal daily routines
by 2-3 months, compared to one month for none TBI
patients.
It was conﬁrmed that increased lymphodepletion was
associated with increased circulating levels of homeostatic
cytokines IL-7 and IL-15 with 12-Gy TBI achieving the
highest concentrations of the serum cytokines [18]. In
addition, it was shown that OR was correlated with telomere
length of the transferred cells.
A major disadvantage ofthe TBI trials was again the high
drop-out rate. Alike the Selected-TIL protocol the majority
of patients did not have TIL applying to the IFNγ criterion.
Additionally, transfusion of autologous CD34+ stem cells is
required after TBI, but suﬃcient numbers ofstem cells could
notbeisolatedforeverypatient,thusincreasingthedrop-out
rate even more.
Overall, using NMC was proven as a necessary and
essential step in the ACT therapy and TBI was shown
to augment lymphodepletion and thereby increases the
response rate. However, this conclusion must be interpreted
with caution as this was not a randomized trial. Statistically,
the 72% response rate achieved in 12-Gy TBI group was
not signiﬁcantly diﬀerent from the 52% or 49% response
rate seen in the other groups, but induced severe additional
toxicities. Therefore, this study should be continued with
more patients to verify the high response rate.
4.GeneticallyEngineered T Cells
One of the possibilities for improving ACT for metastatic
melanoma and other cancer patients is based on the transfer
of genetically modiﬁed peripheral T cells instead of TIL.
Genetically engineered T cells may overcome several disad-
vantages of the TIL protocol. The TIL protocol encounters
several diﬃculties, for example, generating TIL cultures is a
technical challenge and requires high laboratory skills [36].
Using this approach, patients have to undergo surgery in
order to resect tumor tissue for TIL isolation and TIL are a
heterogenic cell mixture with unknown antigen speciﬁcity.
In addition, the endogenous T cell repertoire is not always
responsive to deﬁned tumor-associated antigens such as
self-antigen due to developed tolerance [51, 52]. Finally,
the drop-out rates of enrolled patients can be quite high,
as discussed earlier [36]. These disadvantages led to the
investigation of an alternative method producing tumor-
reactive T cells. The idea is to create T cells with desired
antigenspeciﬁcityandtherebytoenhancetheeﬀectivenessof
ACT therapy [53,54].GeneticmodiﬁcationofTcellsisbased
on the generation of tumor-targeted T cells through the
genetic transfer of antigen-speciﬁc receptors, which consist
of either MHC-restricted T cell receptors (TCR) or non-
MHC-restricted synthetic chimeric antigen receptors (CAR)
[55].Thegeneticapproach ismoreconvenienttothepatients
as itskips surgeryandonlyrequirespatient’sleukopheresisto
obtain peripheral T cells for genetic modiﬁcation.
4.1. Artiﬁcial αβ TC e l lR e c e p t o r s . This approach utilizes the
transfer of cloned cDNAs encoding the α and β chains of
a tumor antigen-speciﬁc TCR into peripheral T cells by an
integrating vector and thus enables the production of large
numbers of tumor speciﬁc T cells [53, 54]. In an initial
clinical trial, metastatic melanoma patients were treated
with autologousTlymphocytestransduced with retroviruses
encoding TCR with low aﬃnity for melanoma-associated
antigen MART-1 [56]. These lymphocytes were adminis-
trated to patients preconditioned with NMC followed by
high-dose bolus IL-2 (Table 1,r o wF ) .T w oo f1 7p a t i e n t s
(12%)underwent regression ofliverand lungmetastasesand
exhibited sustained levels of circulating engineered cells oneClinical and Developmental Immunology 7
year post-infusion. All the other patients exhibited durable
cell engraftment of at least 2 months postinfusion, but did
not respond. This study demonstrates the feasibility of using
genetically engineered T cells for ACT.
Although response rates were still low (12%) as opposed
to 50%–70% in TIL-ACT therapy, this was the ﬁrst evidence
that genetic-engineered T cells can indeed induce clinical
response in advanced cancer patients. This encouraging
approach is only at its beginning and still needs to be
improved. Some of the approaches that may increase the
expression and function of the transgene are being studied,
including the use of diﬀerent vectors, the introduction of
powerful promoters speciﬁc to T cells, and the employment
of higher-aﬃnity TCRs. Latest clinical trials are testing new
TCRs that recognize a broad array of cancer antigens such
as p53, gp100, carcinoembryonic antigen and the NY-ESO-
1 antigen of the cancer testis [57–59], which may enable
targeting of other cancer types in addition to melanoma.
The maindisadvantage ofusinggenesencodingTCRthat
target just one tumor antigen is that they are likely to be
less eﬀective. Tumors are highly heterogeneous and antigen
expression diﬀers markedly between tumors not only among
individual patients, but even within deposits of the same
patient. Investigators should also take into consideration the
potency of antigen/MHC downregulation or loss in tumors.
Another limitation of this approach is its HLA-restriction.
In 2009, Johnson et al. conducted a clinical study with
36 patients treated with high aﬃnity human TCR to MART-
1( Table 1, row G) and mouse TCR to gp100 (Table 1,r o w
H) [60]. Objective cancer regressions were seen in 30%
(6 of 20) and 19% (3 of 16) of patients who received
TCR to MART-1 and gp100, respectively. TCR-transduced
cells persisted at high levels in the blood of all patients
one month after treatment. However, patients exhibited
destruction of normal melanocytes in the skin, eyes, and
ears and sometimes required local steroid administration in
order to treat uveitis and hearing loss [60]. This observation
suggests that great caution must be taken in the selection of
target antigens to prevent severe toxicity of normal tissues
that express the same antigen.
4.2. Chimeric Antigen Receptor (CAR). CARs combine anti-
gen speciﬁcity and T cell activating properties in a single
fusion molecule. The CAR construct which is retrovirally
inserted into normal T lymphocytes, is generated by the
fusion of the variable region of the heavy and light chains
of a monoclonal antibodies with the T cell signaling chains
derived from CD28, 41BB, or CD3ζ [61]. While, clinical
studies in patients with various cancers treated with CAR
have induced only modest responses [62–64], a diverse
array of receptors with diﬀerent functional properties are
now rapidly expanding and may provide a more signiﬁcant
assessment for this approach [65–67]. Since CARs bind the
tumor antigen in an HLA-unrestricted manner, they are
resistant to tumor escape mechanisms related HLA down-
regulation and broadly applicable to patients irrespective of
their HLA type [63, 64, 68].
To date,thereare nopublishedclinicalstudiesusing CAR
in ACT therapy for melanoma; nevertheless, in vitro studies
utilizing chimeric receptor against melanoma antigens such
asganglioside GD2,GD3,and MAGE-A1were reported [69–
71]. Lately, a preclinical study using SCID mice showed that
the overexpression of GD2 by human melanoma cells allows
these cells to be targeted in vitro and in vivo by GD2 CAR-
expressing T cells [69]. Moreover, this study demonstrated
that incorporation of endodomains from both CD28 and
OX40 molecules mediate costimulation of T lymphocytes,
inducing T cell activation, proliferation, and cytotoxicity
against GD2-positive melanoma cells.
A major concern of the CAR approach is the toxicity
proﬁle. T cells encoding CAR for tumor antigens may
be highly potent, but as most tumor-associated antigens
are expressed on normal tissues as well, the potential for
toxicity is obvious. A clinical study with renal cell carcinoma
patients had to be detained as three patients developed
cholestasis due to the high expression of the target antigen,
carbonic anhydrase on normal tissue [63]. A case report on
a metastatic colon cancer patient using CAR targeting the
ERBB2 tumor antigen, described respiratory distress of the
patient within 15 minutes after cell infusion and displayed a
dramatic pulmonary inﬁltrate on chest X-ray [72].
In summary, T cells transduced with genes encoding for
artiﬁcial TCR or CAR, enforce tumor antigen recognition,
improve T cell survival, generate memory lymphocytes, and
reduces T cell death, anergy and immune suppression [55].
Another important advantage of these approaches is the use
of patients’ circulating lymphocytes with no need of surgical
resection and the ability to produce any desired vector.
However, this approach demands high laboratory skills and
expertise and requires longer culture durations resulting in
high costs. The toxicity proﬁle must be improved and more
trials need to be conducted to establish this technology.
5.FutureChallengesofACT
In order to improve ACT for the treatment of human cancer
extensive numbers of studies are being performed. Clinical
trials for diﬀerent ACT studies that are currently recruiting
patients are summarized in Table 2.P e r h a p st h em o s t
important trial on this list is a randomized phase II study
comparing CD8 enriched Young-TIL ACT to treatment with
high-dose IL-2 alone (Table 2, NCT01118091).In fact, this is
the ﬁrst randomized study which will ﬁnally reveal the true
value of TIL ACT versus standard of care. Many ACT centers
worldwide await the results of this study with great interest.
Many studies aim at identifying both patients and
cell parameters that are associated with objective clinical
responses. In this chapter, we will discuss some of them,
including (1) the use of less diﬀerentiated T cells, (2)
identiﬁcation of the exact T cell subpopulation responsible
for response, (3) combination of ACT with monoclonal
antibodies, (4) genetic engineering of new vectors, and (5)
reduction of toxicity.
The persistence of the transferred cells has been clearly
correlated to clinical response in previous reports [42–
46]. One of the factors that inﬂuence persistence is the
diﬀerentiation state of the transferred T cells. Mouse models
showed that early eﬀector T cells mediate better anti-tumor8 Clinical and Developmental Immunology
response than intermediate and late eﬀector T cells due to
theirhighproliferativeandsurvivalpotentialandtheirability
to secrete IL-2 [73, 74]. Studies in humans also support this
preclinical ﬁnding showing that less diﬀerentiated T cells are
moresuitableforACT [42,44,75].Longtelomerelengthand
high CD27 expression are markers of less diﬀerentiated cells
which appear to correlate with persistence and anti-tumor
response [42, 46, 76]. Addition of molecules inhibiting
diﬀerentiation during T cell expansion, modiﬁcation of the
large-scale expansion protocol, transduction of TCR or CAR
into less diﬀerentiated cells, or the use of other cytokines
besides IL-2 may improve the quality of administrated cells.
I L - 2h a sb e e ns h o w nt ob ea ne ﬀective T cell growth factor
b u ta l s ot op r o m o t et h et e r m i n a ld i ﬀerentiation of T cells
leading to activation-induced cell death [73, 77]. Therefore,
the beneﬁt of other cytokines such as IL-7, IL-15, or IL-
21 administration alone or in addition to IL-2 should be
examined, as recent studies suggest that they may play
important roles in manipulating the ﬁnal T cell phenotype
and diﬀerentiation status [78–80].
Other eﬀorts are aimed at identifying speciﬁc TIL
subpopulations responsible for clinical eﬀectiveness. To date,
littleisknownabouttheunderlyingcompositionandcellular
interactions which determine the degree of TIL reactivity
and consequently how to control TIL reactivity. Oved et al.
preformed a study measuring the subpopulation frequencies
of TIL populations originating from diﬀerent melanoma
patients [81]. This study showed that the frequency of
a single subpopulation cannot predict the collective TIL
reactivity to cancer cells in vitro.H o w e v e r ,b yu s i n gas i m p l e
computationalmodel,onecangenerateasetofmathematical
rules that accurately predict the degree of TIL reactivity in
terms of its subpopulation constituents with 91% sensitivity.
In addition, Oved et al. controlled the in vitro reactivity of
the TIL by manipulating their subpopulation composition,
enabling to turn nonreactive TIL into reactive ones and vice
versa, by simple depletion of speciﬁc subpopulation. Mea-
suring the subpopulation frequencies of TIL from 45 ACT
treated patients is performed these days at our melanoma
research center. Frequencies of hundreds of subpopulations
will be determined by ﬂow cytometry and the correlation
to clinical response will be evaluated by a computational
model. The result of this study will be of great interest as
it may reveal the TIL characterization proﬁle of responding
patients.
The combination of T cell transfer with monoclonal
antibodies blocking CTLA-4 or PD-1 function should also
be evaluated in future studies. CTLA-4 and PD-1 are known
to hinder T cell function via blockade of costimulatory
signals. Therefore, addition of those antibodies could avoid
the inhibitory eﬀects of CTLA-4 or PD-1 on transferred T
cells.
A lot of eﬀorts have been invested in the ﬁeld of genetic
engineered lymphocytes utilizing genes encoding αβTCR
andCARtotargetTAA.Genetic-engineering alsoenablesthe
production of T cells with other functions besides TAA rec-
ognition. Modiﬁed T cells might constantly express costim-
ulatory molecules like CD28, produce autocrine cytokines
such as IL-2, express homing molecules (e.g., CD62L) or
prevent apoptosis by the expression of antiapoptotic genes
(e.g., bcl-2). Genetic approaches provide a platform for
further developments in immunotherapy and will direct
ACT to a new era of antitumor therapy.
Another important aim is the reduction of the side
eﬀects related to the treatment. Establishing cells for ACT at
the laboratory is challenging, but great eﬀorts are required
from clinicians as well. Most grade III and IV toxicities
are directly related to the intravenously administration of
high-dose bolus IL-2 (720,000IU/kg, every 8h) after cell
transfer [16, 24]. Reducing the dose of IL-2 signiﬁcantly
decreases toxicity [82, 83]. Many current trials (Table 2)a r e
therefore using low-dose subcutaneous IL-2 administration
in order to relieve the patients. Subcutaneous low-dose IL-
2 administration also minimizes the costs of the treatment
as its administration does not require hospitalization. A
combined approach of Young-TIL ACT with subcutaneous
low-dose IL-2 should be evaluated in the future. This
combination drastically simpliﬁes the laboratory and clinical
eﬀorts and could allow the widespread applicability of
ACT.
6.Conclusions
Melanoma has been widely studied as a target for
immunotherapy because it has been considered more sus-
ceptible to immune attack than other tumors. Adoptive T
cell transfer has not only shown promising clinical results in
the last decade but also provides a platform for the future.
In the coming years, the use of advanced protocols will
surely enhance the anti-tumor reactivity of transferred cells.
Sophisticated genetic approaches are of great potential in the
future, but so far TIL ACT is the most eﬀective cell therapy
for metastatic melanoma patients, with objective responses
in more than 50% of the patients. Simplifying the TIL
production process, by using Young-TIL, may enable cancer
centers worldwide to implement this eﬀective approach and
expose more patients to ACT therapy.
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